Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD30/CD3 bispecific antibody GEN3017

An Fc-silenced immunoglobulin G1 (IgG1) bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD30 (tumor necrosis factor receptor superfamily member 8; TNFRSF8) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD30/CD3 bispecific antibody GEN3017 targets and binds to both CD30 on the surface of tumor cells and CD3 on T cells. This results in the cross-linking of tumor cells and T cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor receptor superfamily, is overexpressed on the surfaces of certain tumor cells.
Synonym:anti-CD30/anti-CD3 bispecific antibody GEN3017
CD30 x CD3 bispecific antibody GEN3017
DuoBody CD3xCD30 GEN3017
DuoBody GEN3017
Code name:GEN 3017
GEN-3017
GEN3017
Search NCI's Drug Dictionary